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Treatment  of  dominantly  inherited  muscle  disorders 
remains a difficult task considering the need to eliminate 
the pathogenic gene product in a body-wide fashion. 
We show here that it is possible to reverse dominant 
muscle disease in a mouse model of facioscapulohumeral 
muscular dystrophy (FSHD). FSHD is a common form of 
muscular dystrophy associated with a complex cascade 
of epigenetic events following reduction in copy number 
of D4Z4 macrosatellite repeats located on chromosome 
4q35. Several 4q35 genes have been examined for their 
role in disease, including FRG1. Overexpression of FRG1 
causes features related to FSHD in transgenic mice and 
the FRG1 mouse is currently the only available mouse 
model of FSHD. Here we show that systemic delivery 
of  RNA  interference  expression  cassettes  in  the  FRG1 
mouse, after the onset of disease, led to a dose-depen-
dent long-term FRG1 knockdown without signs of tox-
icity. Histological features including centrally nucleated 
fibers, fiber size reduction, fibrosis, adipocyte accumula-
tion, and inflammation were all significantly improved. 
FRG1 mRNA knockdown resulted in a dramatic resto-
ration  of  muscle  function.  Through  RNA  interference 
(RNAi) expression cassette redesign, our method is ame-
nable to targeting any pathogenic gene offering a viable 
option for long-term, body-wide treatment of dominant 
muscle disease in humans.
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IntroductIon
Facioscapulohumeral  muscular  dystrophy  (FSHD)  is  the  third 
most common human myopathy, with an incidence of 1 in 15,000 
in the general population.1 The disease is characterized by progres-
sive degeneration of a highly selective set of muscle groups. As its 
name suggests, weakness first arises in facial mimic and shoulder 
girdle muscles. The disease can then progress to abdominal mus-
cle leading to abdominal protrusion and spine lordosis. In more 
severe cases, muscle degeneration reaches foot dorsi-flexor and 
pelvic girdle muscles impairing the ability to walk. In addition to 
the muscular dystrophy, 50–75% of FSHD patients develop retinal 
vasculopathy highlighting the complex pathophysiology of FSHD.
FSHD has not been linked to a classical mutation within a 
protein-coding gene and several lines of evidence suggest that 
FSHD derives from the interplay of complex genetic and epige-
netic events.2 In 95% of cases (FSHD1A, OMIM 158900), the dis-
ease is associated with reduction in copy number within a large, 
complex tandem array, called D4Z4, located in the subtelomeric 
region of chromosome 4 (4q35).3 While it is generally agreed that 
deletion of D4Z4 units causes epigenetic changes leading to the 
overexpression of genes present within the FSHD region, there 
are opposing opinions regarding support for a role for the D4Z4 
repeat gene DUX44 and a proximal gene FRG1.5 While efforts to 
produce a mouse model based on expression of DUX4 have not 
succeeded, FRG1-expressing mice develop a disease with physi-
ological, histological, ultrastructural, and molecular features of 
FSHD. FRG1 is a highly conserved gene6 encoding for a dynamic 
nuclear and sarcomeric protein.7 In the nucleus, FRG1 is involved 
in RNA processing and colocalizes with proteins mutated in other 
neuromuscular disorders.8–11 In mature muscles, FRG1 localizes 
also to the sarcomeric Z-disc.7 Interestingly, in FSHD patients 
mild  sarcomeric  defects  have  been  reported.12  Notably,  many 
other myopathies are caused by mutations in genes encoding for 
sarcomeric proteins.13–15 Most importantly, overexpression studies 
in three different animal models indicate that FRG1 is the only 
FSHD candidate gene able to recapitulate both muscular and vas-
cular FSHD-like defects.5,16–18 Collectively, these results suggest 
that the FRG1 mouse is a valid model of FSHD.
There is no treatment for FSHD. The most straightforward 
therapeutic approach would be to eliminate the gene product that 
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governs all pathogenic processes. We have developed a method, 
based  on  RNA  interference  (RNAi)  to  inhibit  FRG1-mediated 
muscle pathology in the FRG1 mouse model for restoration of 
muscle function. RNAi is a fundamental cellular mechanism for 
silencing gene expression19 and is currently one of the most prom-
ising new approaches for disease therapy (reviewed in ref. 20).
For an efficient systemic delivery of RNAi to a difficult target 
tissue like the skeletal muscle, one promising strategy consists in 
the use of engineered viruses to express short hairpin RNAs (shR-
NAs).21–23 Among the viral systems being utilized today, one that 
has generated much optimism is recombinant adeno-associated 
virus (rAAV) (reviewed in ref. 24). rAAVs possess several char-
acteristics that make them interesting for gene therapy including 
absence of pathogenicity in humans, broad tissue tropism, and 
ability to infect postmitotic cells. Numerous AAV serotypes with 
preferential tropism for different tissues have been identified.25–27 
Intravenous administration of various rAAVs has proven success-
ful at correction of disease in several animal models leading to a 
growing number of clinical trials to treat human disease such as 
hemophilia B, Parkinson’s disease, and cystic fibrosis.24 A single 
intravenous  administration  of  rAAV  serotype  6  (rAAV6)  was 
shown to cause a body-wide transduction of the entire skeletal 
musculature28 and was used for gene therapy studies of Duchenne 
muscular dystrophy in mice.29 Recently, AAV6 delivery of thera-
peutic mini-dystrophin genes to larger animal models for long-
term expression demonstrated success in preclinical studies.30
In contrast to gene replacement for disease therapy, we evalu-
ated  the  feasibility  of  combining  rAAV6  delivery  and  RNAi-
mediated mRNA knockdown as a possible therapeutic approach 
for a dominant muscle disorder. We show that a single injection 
of rAAV6 expressing FRG1 shRNAs into the tail vein of FRG1 
animals already showing signs of muscular dystrophy is safe and 
sufficient to obtain long-term FRG1 knockdown. rAAV6 FRG1 
RNAi systemic application resulted in a significant histological, 
molecular, and functional rescue of the phenotype. This study 
opens  a  route  to  clinical  application  of  single-dose,  long-term 
RNAi therapy for the treatment of FSHD and other dominant 
muscular dystrophies.
results
selection of a rAAV6-shrnA that efficiently 
downregulates FRG1 expression
In order to efficiently downregulate the FRG1 mRNA, we designed 
three different shRNAs (sh1-, sh2-, sh3-FRG1) (Figure 1a). The 
three shRNAs were cloned into a rAAV plasmid containing an 
RNAi expression cassette under the control of a human U6+27 
snRNA  promoter  upstream  of  the  a  human  placental  alkaline 
phosphatase  reporter  gene  (hPLAP)  rAAV6-sh1FRG1,  rAAV6-
sh2FRG1, rAAV6-sh3FRG1) (Figure 1a).31
Viruses were initially tested for their ability to downregulate 
FRG1 in tissue culture by transducing C2C12 muscle cells over-
expressing FRG1.5 After 48 hours, FRG1 messenger RNA levels 
were  analyzed  using  real-time  reverse  transcriptase  RT-PCR. 
As  shown  in  Figure  1b,  the  FRG1  downregulation  achieved 
with rAAV6-sh1FRG1 (0.52 ± 0.06, P < 0.01) was stronger com-
pared to the one obtained with the other two viruses (0.67 ± 
0.062 and 0.73 ± 0.08, for rAAV6sh2FRG1 and rAAV6sh3FRG1, 
respectively). At protein level, a significant dowregulation follow-
ing virus transduction was reached only with rAAV6-sh1FRG1 
(Figure 1c). Based on these data, we selected rAAV6-sh1FRG1 
for further tests in vivo.
dose-dependent transduction of the entire skeletal 
musculature and long-term FRG1 silencing
To evaluate the transduction potential of rAAV6-sh1FRG1 after 
systemic  delivery,  FRG1  mice  were  administered  two  different 
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Figure 1  design and in vitro efficacy of recombinant adeno-associ-
ated virus serotype 6 (rAAV6) driving expression of short hairpin 
rnAs (shrnAs) against FRG1. (a) Schematic representation of rAAV6 
vector where shRNA sequences against FRG1 (sh1, sh2, and sh3) are 
under the control of the U6 promoter. Rous Sarcoma Virus (RSV) pro-
moter  drives  expression  of  human  placental  alkaline  phosphatase 
(hPLAP).  (b)  Residual  mRNA  level  of  FRG1  after  infection  of  C2C12 
myoblasts overexpressing FRG1 with rAVV6 vector expressing sh1-, sh2- 
or  sh3-FRG1  sequences.  The  values  were  determined  using  real-time 
reverse transcriptase-PCR. (c) Residual protein level of FRG1 in the same 
sample as in panel b. A representative picture of the immunoblotting 
(top), and the quantification measured by densitometry (bottom) are 
shown. C, mock infected cells; sh1, rAAV6-sh1FRG1 infected-cells; sh2, 
rAAV6-sh2FRG1 infected-cells; sh3, rAAV6-sh3FRG1 infected-cells. Error 
bars represents mean + SD, n = 5. P < 0.05 and P < 0.01 are represented 
by one or two asterisks, respectively.Molecular Therapy  vol. 19 no. 11 nov. 2011  2057
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doses of 2 × 1012 or 5 × 1012 vector genomes (vg), or vehicle as 
control, through the tail vein at 6 weeks of age. Importantly, at 
this age FRG1 mice are already showing significant histological 
changes, such as reduction in muscle fiber cross-sectional area 
(CSA), increased percentage of centrally nucleated muscle fibers 
and  inflammation  (A.  Xynos,  M.V.  Neguembor,  M.C.  Onorati, 
P. Picozzi, D. Licastro, S. Bortolanza et al., in preparation). At 12 
weeks postinjection, individual muscles were dissected and stained 
for the alkaline phosphatase reporter to determine the extent of 
transduction at the single muscle fiber level. As shown in Figure 2, 
all skeletal muscles analyzed confirmed the presence of the virus 
and displayed dose-dependent transduction. With the higher viral 
dose, all the muscles analyzed showed uniform transduction with 
greater than 80% positive muscle fibers. In contrast, with the lower 
dose the transduction was much less efficient and none of the mus-
cles reached more than 45% of positively transduced muscle fibers 
(Figure 2a,b). Similar results were obtained by analyzing the level 
of mRNA of hPLAP by real-time RT-PCR in the different muscles. 
Indeed, the overall hPLAP expression level was between 6- (vastus 
lateralis) and 18- (tibialis anterior) fold higher at the higher viral 
dose as compared with the levels obtained in the same muscles 
injected with the lower viral dose (Figure 2c).
We  next  determined  whether  the  transduction  efficiency 
observed with the high dose of virus would translate into a higher 
level  of  FRG1  muscle  silencing.  Using  real-time  RT-PCR,  we 
found that the high viral dose of 5 × 1012 vg caused a significant 
reduction of FRG1 expression in all muscles analyzed (P < 0.01 for 
vastus, P < 0.05 for other muscles) (Figure 3a). On the contrary, 
the viral dose of 2 × 1012 vg had no significant effect on mRNA 
levels of FRG1, indicating that the muscle transduction obtained 
was not sufficient to obtain a reproducible FRG1 downregulation 
(Figure 3a).
In order to verify whether the downregulation observed at the 
RNA level with the high rAAV6-sh1FRG1 dose translated into a 
downregulation at protein level, immunoblotting was performed 
to analyze FRG1 levels. We observed a reduction of FRG1 pro-
tein of 48–71% in the muscles analyzed as shown in Figure 3b 
and quantified in Figure 3c. Overall, our results indicate that a 
single rAAV6-sh1FRG1 systemic administration is sufficient to 
transduce the entire skeletal musculature and obtain significant 
long-term FRG1 silencing.
rAAV6-sh1FRG1 treatment appears safe in mice
Although RNAi therapy in mice and humans appear to be gener-
ally effective and well tolerated, there are a number of reports from 
animal studies that caution against the use of high-dose in vivo as 
it can lead to oversaturation of the endogenous RNAi pathway.32–35 
Co-option of this pathway to suppress a specific disease gene could 
have  adverse  effects  by  interfering  with  the  normal  biological 
function of microRNAs (miRNAs) in targeted organs. Treatment 
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Figure 2  transduction efficacy following systemic delivery of rAAV6-
sh1FRG1. A total of 2 × 1012 or 5 × 1012 rAAV6-sh1FRG1 viral genomes 
(vg) were administered by tail vein in 6-week-old FRG1 overexpressing 
mice. Vastus lateralis, biceps brachii, gastrocnemius and tibialis anterior 
were harvested 12 weeks later. (a) Human placental alkaline phosphatase 
(hPLAP) activity in sections of skeletal muscles stained with the BCIP/
NBT substrate. Representative images obtained using a ×10 objective 
are shown. (b) Quantification of hPLAP-positive myofibers in the indi-
cated muscles. The percentage of hPLAP-stained myofibers versus total 
number of myofibers in the section is represented. Five fields for each 
muscle and three mice per group were analyzed. Values obtained from 
the mice injected with the dose of 2 × 1012 vg or 5 × 1012 vg are shown 
by black or white columns, respectively. Error bars represents mean + 
SD, n = 3 P < 0.001 is represented by three asterisks. (c) Real-time reverse 
transcriptase-PCR for hPLAP mRNA expression. The value obtained with 
the dose of 5 × 1012 vg (white bars) was related to the corresponding 
value obtained with the dose of 2 × 1012 vg (black bars) for each differ-
ent muscle type.2058  www.moleculartherapy.org  vol. 19 no. 11 nov. 2011     
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toxicity primarily correlated with shRNA dose and could be over-
come  by  expressing  extended  hairpins  such  as  miRNA-based 
hairpins that incorporated RNAi target sequences.33,34 Therefore, 
achieving tissue tropism combined with efficacy-related shRNA 
expression levels, without overexpression, is important to mini-
mize the risk of side effects from RNAi therapy. We combined a 
muscle-tropic AAV serotype, AAV6, with a human U6 expression 
cassette containing a 27 nucleotide 5′ leader for stabilization of 
the transcript and a 3′ poly(U) terminator.31 In this setting we did 
not observe any adverse events related to treatment with FRG1-
targeted  hairpins.  Safety  of  rAAV6-sh1FRG1  was  evaluated  at 
multiple levels and time points after systemic delivery. As previ-
ously reported28 and shown in Supplementary Figure S1a, liver 
and the heart are two vital organs efficiently transduced by AAV6. 
We collected blood samples 1, 4, and 8 weeks after the injection to 
measure the serum activity of alanine transaminase levels for an 
indication of liver toxicity. Supplementary Figure S1b shows that 
rAAV6-sh1FRG1 transduced mice displayed comparable serum 
alanine aminotransferase activity to saline injected or wild-type 
mice at all timepoints, including 4 weeks postinjection, the peak 
of liver toxicity observed by others assaying AAV-mediated RNAi 
cassette expression in liver.32 Histological analysis showed that liv-
ers of treated mice were indistinguishable from those of untreated 
animals indicating an absence of ongoing liver toxicity of rAAV6-
sh1FRG1 (Supplementary Figure S1c). We also looked for loss 
of cardiomyocytes, since cardiomyocyte death in the ventricular 
wall and associated dilated cardiomyopathy results from inhibi-
tion of the miRNA pathway necessary for normal heart function.36 
As shown in Supplementary Figure S1c, histological analysis of 
rAAV6-sh1FRG1 transduced hearts did not showed any signs of 
toxicity as no lesions were detected. Furthermore, we considered 
the potential for unintended changes in skeletal muscle caused by 
the therapy. As a measure of fiber integrity, we analyzed expres-
sion and distribution of dystrophin that is normally positioned 
at the membrane of muscle fibers. As shown in Supplementary 
Figure S2a, integrity of the sarcolemma was unaffected by rAAV6 
treatment as demonstrated by normal localization of dystrophin. 
Next,  we  measured  expression  of  the  inflammatory  cytokines, 
interleukin-10  and  tumor  necrosis  factor-α ( Supplementary 
Figure S2b). rAAV6-sh1FRG1 treated animals displayed a level of 
inflammation reduced compared to vehicle-treated FRG1 animals. 
Additionally, in order to exclude that rAAV6-mediated sh1FRG1 
expression  interfered  with  miRNA  production  pathways,  we 
analyzed the levels of miRNA expression in different tissues. As 
shown in Supplementary Figure S2c, the expression of the miR-
NAs analyzed was comparable in vehicle and rAAV6-sh1FRG1 
treated FRG1 mice. Altogether, our analyses indicate that long-
term rAAV6-sh1FRG1 treatment is safe.
A single intravenous injection of rAAV6-sh1FRG1 
rescues muscle histopathology of FRG1 mice
Based on our observation that a single systemic administration of 
5 × 1012 vg of rAAV6-sh1FRG1 is safe and is sufficient to obtain 
high transduction levels and significant long-term downregula-
tion of FRG1 expression in all muscles analyzed, we proceeded 
to evaluate long-term therapeutic efficiency of rAAV6-sh1FRG1. 
We administered virus at 6 weeks of age, past the onset of dys-
trophic  muscle  changes  (A.  Xynos,  M.V.  Neguembor,  M.C. 
Onorati, P. Picozzi, D. Licastro, S. Bortolanza et al., in prepara-
tion). Animals were analyzed 3 months postinjection of a single 
dose of 5 × 1012 vg. We focused our analysis on vastus lateralis, 
a muscle highly affected in FRG1 mice and in FSHD patients.5 
Histological examination of Gömöri trichrome stained muscle 
sections revealed a general qualitative improvement in fiber size 
and muscle architecture (Figure 4a). Analysis of several mus-
cular  dystrophy  parameters  revealed  a  significant  quantitative 
rescue. First, there was a 30% reduction (P < 0.001) in centrally 
nucleated  myofibers  in  the  vastus  muscle  of  rAAV6-sh1FRG1 
treated  animals,  indicating  an  inhibition  of  muscle  degenera-
tion and regeneration processes (Figure 4b). Second, morpho-
metric analysis to determine the individual muscle fiber CSA 
showed that the distribution of CSA in rAAV6-sh1FRG1 treated 
mice  was  significantly  different  than  the  vehicle-treated  mice 
(Kolmogorov–Smirnov test) (Figure 4c). The CSA distribution 
curve was shifted right or toward larger overall fiber area for the 
rAAV6-sh1FRG1 treated animals compared to vehicle-injected 
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Figure 3  efficient FRG1 downregulation following systemic admin-
istration of rAAV6-sh1FRG1. (a) A total of 2 × 1012 vg or 5 × 1012 
vg rAAV6-sh1FRG1 were administered by tail vein in 6-week-old FRG1 
overexpressing  mice.  Vastus  lateralis,  biceps  brachii,  gastrocnemius 
and tibialis anterior were harvested 12 weeks later. Real-time reverse 
transcriptase-PCR  for  FRG1  mRNA  expression  is  represented.  Values 
obtained from the mice injected with the dose of 2 × 1012 vg or 5 × 1012 
vg are shown by black or white columns, respectively. Values were nor-
malized versus vehicle-injected mice (n = 3). (b) Representative FRG1 
and tubulin immunoblotting of muscles following systemic injection 
with 5 × 1012 vg. V, vehicle-injected; rAAV6, rAAV6-sh1FRG1-injected. 
(c) Immunoblotting quantification. Error bars represents mean + SD, 
n = 3. P < 0.05 and P < 0.01 are represented by one or two asterisks, 
respectively.Molecular Therapy  vol. 19 no. 11 nov. 2011  2059
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controls. The increase in muscle fiber CSA of the treated mice 
was more similar to that of age-matched wild-type control ani-
mals (Figure 4c). This result is also supported by the average 
CSA of rAAV6-sh1FRG1 treated animals, which was increased 
by 30% (P < 0.001) compared to that of vehicle-treated control 
mice (Figure 4d). Third, we evaluated fibrosis in the treated mice, 
a common characteristic of dystrophic muscle. Sirius red staining 
for fibrosis-associated collagen deposition indicated that treated 
muscles displayed a 35% (P < 0.001) less collagen protein than 
controls (Supplementary Figure S3). Fourth, Oil Red O stain-
ing showed more than 50% (P < 0.01) less adipose tissue than in 
saline-treated mice (Supplementary Figure S4), a replacement 
for loss of muscle tissue commonly associated with dystrophic 
muscle changes. Finally, immunohistochemistry staining against 
CD45,  a  surface  marker  for  all  cells  of  hemopoietic  origin, 
showed a 44% (P < 0.001) decrease of the inflammatory infiltrates 
in treated animals, consistent with the reduction in inflammatory 
cytokines shown in Supplementary Figure S2 (Supplementary 
Figure S5). Collectively, these results show that a single systemic 
delivery of rAAV6-sh1FRG1 is sufficient to obtain a significant 
rescue in muscle histopathology of FRG1 mice.
rAAV6-sh1FRG1 rescues muscle function
Our results show that rAAV6-sh1FRG1 can mediate long-term 
FRG1 downregulation that results in an amelioration of muscle 
histopathology. Therefore, we wanted to determine whether the 
improvement in histopathology observed also reflected improve-
ment in muscle function. For this purpose, we decided to perform 
exercise tolerance tests. Animals injected with rAAV6-sh1FRG1, 
vehicle-treated animals or wild-type mice underwent a treadmill 
running test during the 11-week post-transduction period and were 
monitored for the length of time necessary to reach exhaustion. As 
shown in Figure 5 and in the online video (Supplementary Video 
S1), rAAV6-sh1FRG1-treated animals showed an improvement in 
performance as early as 5 weeks after treatment and by the end of 
the 11-week test period their performance was indistinguishable 
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Figure 4  significant rescue of muscle morphology after a single injection with rAAV6-sh1FRG1. 5 × 1012 vg of rAAV6-sh1FRG1 were administered 
in the tail vein in 6-week-old FRG1 overexpressing mice. Twelve weeks after the injection, the vastus lateralis were analyzed by Gömöri trichrome 
staining. Vehicle-injected FRG1 mice and age-matched wild-type (WT) mice were used as control. (a) Representative vastus lateralis sections obtained 
using a ×20 objective. Bar = 50 µm; (b) Centrally nucleated fibers were counted in vastus lateralis of the different mice groups and represented 
as percentage of total myofibers; (c) Cross-sectional area (CSA) was measured in vastus lateralis and the average of each group is represented; 
(d) Distribution of fiber area. Error bars represents mean + SD, n = 5 per vehicle- and rAAV6-sh1FRG1-injected mice, n = 3 per age-matched WT mice. 
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from wild-type animals, indicating that their functional recovery 
was complete. In contrast, vehicle-treated mice, in which disease 
progression continued, did not display any improvement in run-
ning capability throughout the test (Figure 5).
reversal of disease is specific to FrG1 downregulation
Our analyses of rAAV6-sh3FRG1 did not show any significant 
knockdown activity of FRG1 mRNA or protein with widespread 
transduction  of  muscle  (Figure  1),  so  we  decided  to  test  this 
viral preparation further in FRG1 mice to rule out the possibil-
ity of RNAi nonspecific effects of rAAV6-sh1FRG1 treatment. As 
shown in Figure 6, injection of 5 × 1012 vg of rAAV6-sh3FRG1 was 
very effective in transducing several muscles but did not cause any 
FRG1 downregulation. Interestingly, we also did not observe any 
histological or functional phenotypic rescue in FRG1 mice with 
rAAV6-sh3FRG1 treatment (Figure 6). These results indicate that 
the phenotypic rescue is specifically due to FRG1 knockdown.
dIscussIon
Muscular dystrophies pose a major public health problem since 
they are common, incurable disorders that result in significant 
disability or death. Historically, FSHD was thought of as the third 
most prevalent muscular dystrophy. Notably, new epidemiologi-
cal data suggest that FSHD could be the most prevalent muscular 
dystrophy followed by Duchenne/Becker and myotonic dystro-
phies:  http://www.orpha.net/consor/cgi-bin/Education_Home.
php?lng=EN. So far, development of therapeutic approaches for 
muscular  dystrophies  has  been  mainly  focused  on  Duchenne 
muscular dystrophy. Understanding the complex mechanism of 
disease development for FSHD has slowed therapy development 
and, until the work we describe here, there was little prospect for 
a treatment for FSHD.
It is generally agreed that FSHD results from gene overexpres-
sion.2 For this reason, FSHD provides an ideal opportunity to 
explore the therapeutic potentials of RNAi-mediated gene silenc-
ing. Since FSHD is caused by a single event (gene overexpression 
following D4Z4 deletion), our RNAi therapeutic approach would 
be applicable to all patients. Moreover, FSHD has a delayed onset, 
and through molecular genetic testing, individuals carrying the 
molecular defect can be identified long before they present clini-
cal signs of muscular dystrophy. Hence, there is a considerable 
therapeutic window where intervention may slow or even prevent 
disease-related muscle deterioration.
Although several intriguing FSHD candidates have been pro-
posed, no single gene has been conclusively linked to FSHD devel-
opment thus far.3 It was reported that the D4Z4 repeat contains 
an ORF encoding a double homeobox protein named DUX4.37 
DUX4  has  been  detected  in  FSHD-derived  primary  myoblasts 
but not in controls, suggesting that D4Z4 may directly affect dis-
ease progression through the aberrant production of DUX4.4,38-40 
Several functional studies described extreme general toxicity for 
DUX4.41–44 Cellular toxicity of DUX4 coupled with very low DUX4 
expression in human cells poses a difficult challenge for modeling 
the human disease in mice. However, if a DUX4 mouse model is 
produced, our approach could be adapted for DUX4 knockdown 
in muscle through retargeting of the RNAi hairpin sequence to 
DUX4 mRNA.
A growing understanding of its function, strongly suggests 
that FRG1 overexpression plays an important role in FSHD.16–18,45 
Based on these data, FRG1 inhibition would be expected to lead 
to a therapeutic benefit in FSHD. Hence, we have used the only 
available FSHD mouse model to provide a proof of principle with 
respect to the use of RNAi therapeutic approaches for FSHD. In 
this study, we demonstrated long-term, dose-dependent reduc-
tion in FRG1 expression in all the muscles analyzed. Therapeutic 
benefits were observed in all of the mice treated with either low or 
high AAV6-sh1FRG1 doses. However, only the high-dose cohorts 
had therapeutic levels of FRG1 knockdown that were sufficient 
and sustainable to obtain a near complete functional recovery. 
The low-dose cohorts were on the threshold of a moderate to 
severe muscle histology phenotype that correlated with clinical 
observations of a variable and minor functional recovery (data 
not shown). Interestingly, we observed variability in skeletal mus-
cle gene transfer efficacy in rAAV6 shRNA-injected FRG1 mice 
injected with lower vector dose (Figure 2 and data not shown) 
suggesting that it was just at the threshold level.
An  indication  that  viral-based  RNAi  expression  cassette 
expression could cause toxicity in mice due to oversaturation of 
the endogenous miRNA pathways came from a study of AAV-
mediated shRNA hairpin expression in liver by Grimm and col-
leagues.32 Toxicity was also reported in the context of targeting 
mutant Huntington’s disease mRNA.34 In both cases, toxicity was 
determined to be a function of shRNA processing and expres-
sion level. Interestingly, Davidson’s group reported that toxicity 
was eliminated when RNAi hairpin sequences were incorporated 
into a naturally occurring miRNA scaffold.34 We selected a version 
of the U6 promoter to achieve levels of expression that might be 
therapeutic in the context of systemic delivery and high transgene 
expresssion. The U6+27 expression cassette had been developed 
for stable nuclear expression and 5′ capping of small RNAs, such 
as ribozymes, to direct cleavage of potential therapeutic targets as 
demonstrated for the TAR sequence from HIV-1 and was adapted 
for expression of hairpin triggers of RNAi.31 Notably, using the 
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Figure  5  Increased  muscles  function  following  single  intravenous 
administration of rAAV6-sh1FRG1 vector. 5 × 1012 vg of rAAV6-sh1FRG1 
were injected in the tail vein of FRG1 overexpressing mice. Treadmill run-
ning exercise was performed during 11 weeks after treatment and the 
time (minutes) to reach exhaustion was recorded. Vehicle-injected mice 
and C57BL/6J mice were used as controls. Error bars represents mean + 
SD, n = 5 per vehicle- and rAAV6-sh1FRG1-injected mice, n = 4 per age-
matched wild-type (WT) mice. P < 0.01 is represented by two asterisk 
and it represents the statistical difference between vehicle and vector-
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Figure 6  Phenotypic rescue is specifically due to FRG1 knockdown. 5 × 1012 vg of the non-silencing rAAV6-sh3FRG1 or rAAV6-sh1FRG1 were 
injected in the tail vein of FRG1 overexpressing mice. Animals were analyzed 12 weeks later. (a) Human placental alkaline phosphatase (hPLAP) activ-
ity in section of skeletal muscles stained with the BCIP/NBT substrate. Bar = 100 µm. (b) Representative images of vastus lateralis Gömöri trichrome 
staining in vehicle-, rAAV6-sh1FRG1- or rAAV6-sh3FRG1-injected FRG1 mice and age-matched wild-type (WT) mice obtained using a ×20 objective. 
(c) Real-time reverse transcriptase-PCR for FRG1 mRNA expression. Values were normalized versus vehicle-injected mice. (d) Centrally nucleated 
fibers were counted in vastus lateralis of different mice group and represented as percentage of total myofibers. (e) Cross-sectional area (CSA) was 
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U6+27 promoter for expression of HIV and lamin A/C RNAi hair-
pin triggers led to efficient suppression of target genes in human 
cells and did not show accumulation of full-length precursors.46 
It is unclear from the small number of RNAi sequences tested 
whether the U6+27 expression cassette will have a safety profile 
in vivo similar to recent tests of miRNA-based RNAi shuttles or 
RNA polymerase II promoter expression cassettes and needs to 
be examined further.33,34 Nevertheless, no long-term evidence of 
toxicity was observed in any of the treated mice using the U6+27 
promoter to express our therapeutic hairpins.
In conclusion, we have shown that we can prevent disease pro-
gression with systemic, AAV6-mediated FRG1 RNAi performed 
following  disease  onset.  This  work  exemplifies  the  power  and 
specificity of RNAi in a widespread tissue in a living animal and 
offers a potential route to clinical application and treatment for 
individuals who are already showing symptoms of disease. The 
efficient, stable, long-term therapeutic reduction of pathological 
signs in the FRG1 mouse suggests the added potential clinical 
benefit of efficacy with limited dosing. This therapy allowed sig-
nificant improvement of disease and could potentially be trans-
lated to human patients. The knowledge gained through these 
studies could facilitate the development of new therapies to treat 
FSHD and other dominant diseases.
MAterIAls And Methods
RNAi hairpin design and cloning. The original RNAi FRG1 targets were 
select using a program previously available on the Promega website based 
on parameters specified in the scientific literature (siRNA Designer, con-
tact Promega, Madison, WI for details). Three FRG1 siRNAs were tested 
in vitro and two were selected for their knockdown efficiency of exog-
enously expressed FRG1 as analyzed by western blot (data not shown). 
From the first target sequence from FRG1 exon 8 shown in Figure 1, 
the full-length (FRG1sh1) and a shortened sequence by 2 nts from the 5′ 
end (FRG1sh2) to increase safety in vivo32 were cloned as hairpins using 
the  overlapping  oligonucleotides:  sh1  =  full-length  5′  ACGCGTCGAC 
AAAGGCTCGGAAAGATGGATTCTTCCTGTCAAA 3′ and 5′ TGCTC 
TAGAAAAGGCTCGGAAAGATGGATTTGACAGGAAGAA  3′;  sh2  = 
5′ ACGCGTCGACAGGCTCGGAAAGATGGATTCTTCCTGTCAAA 3′   
and  5′  TGCTCTAGAAGGCTCGGAAAGATGGATTTGACAGGAAG 
AA 3′. Oligonucleotides designed from the second selected siRNA from 
exon 3 to make FRG1sh3 are as follows: 5′ ACGCGTCGACCCATAGCC 
ATTGAAATGGACTTCCTGTCATC 3′ and 5′ TGCTCTAGACCATAGC 
CATTGAAATGGATGACAGGAAGTC  3′.  These  oligonucleotide  pairs 
were annealed, extended, then restricted with Sal I and Xba I and cloned 
into the Sal I and Xba I sites of the U6+27 expression cassette cloned into 
pARAP4. The full cassette, U6+27-Sal I/Xba I-TTTTT, was derived from 
lentiviral plasmid pLGINm and inserted into pARAP4 (existing Sal I and 
Xba I sites destroyed)47 by blunt-end cloning of Cla I and EcoR I restricted 
fragment into the SnaB I site 5′ of the RSV-hPLAP gene (kind gift from Chao-
Zhong Song, University of Washington, Seattle, WA) described in ref. 48.
Virus production. AAV6 production was essentially as described in ref. 28 
with modification described in ref. 49. Viral genomes were quantitated by 
Southern analysis using a probe to the hPLAP SV40 polyadenylation signal 
as described in ref. 50.
Manipulation  of  experimental  animals.  C57BL/6J  transgenic  mice 
overexpressing  human  FRG1  under  the  control  of  the  human  skeletal 
α-actin gene promoter5 were maintained by crossing them with wild-type 
C57BL/6J mice. FRG1-high mice and control C57BL/6J littermates were 
maintained at Charles River (Calco, Italy). All procedures were approved 
by the Institutional Animal Care and Use Committee of the Fondazione 
San Raffaele del Monte Tabor and were communicated to the Ministry of 
Health and local authorities according to Italian law.
Mice  progeny  were  genotyped  by  PCR  using  the  primers  5′-GA 
TCTAGCGGCCGCCATGGCCGAGTACTCCTATGTGAAGTCT-3′ and 
5′-GCGCGCTTAATTAATCACTTGCAGTATCTGTCGGCTTTCA. 
PCR  conditions  were  as  follows:  initial  denaturation  at  95 °C  for  2 
minutes, 42 cycles with denaturation at 95 °C for 30 seconds, annealing 
at 68 °C for 30 seconds and amplification at 72 °C for 1 minute. Virus 
was administered by intravenous injection via tail vein to 6-weeks-old 
transgenic female mice. In detail, 200 µl containing 2 × 1012 or 5 × 1012 vg 
of vector in physiological solution were injected into the tail vein using a 
25-gauge Terumo syringe (Terumo, Leuven, Belgium). Mice injected with 
an equal volume of physiological solution (vehicle) and wild-type sex and 
age-matched C57BL/6J were used as controls. All mice were evaluated 
during 12 weeks subsequent to treatment.
Cell culture and viral infection. FRG1 overexpressing C2C12 myoblast 
cells  were  previously  described.5  Cells  were  grown  in  DMEM-HIGH 
(Dulbecco’s modified Eagle’s medium, high glucose with sodium pyruvate 
and l-glutamine; EuroClone, Milano, Italy) supplemented with 10% fetal 
bovine serum (EuroClone), 1% penicillin/streptomycin (100 U/ml final 
concentration; EuroClone) and 1 µg/µl Neomycin (G-418; InvivoGen, San 
Diego, CA). All cells were maintained at 37 °C with 5% CO2 in a humidifier 
incubator.
Cells were seeded in 6-well plates with 1 × 104 cells/well and were 
infected 24 hours later with 1010 vg/well of rAAV6 expressing sh1, sh2, 
and sh3. After 3 days, cells were collected for RNA and protein analysis.
Histological analysis. Mice were euthanized by CO2 inhalation or by cer-
vical dislocation. Skeletal muscle tissue specimens were rapidly mounted 
in OCT (Optimal Cutting Temperature compound; Sakura, Zoeterwoude, 
The Netherlands) and then frozen in isopentane cooled in liquid nitrogen. 
Transverse sections (8 µm) were performed on a cryostat and used for the 
analysis described below.
The percentage of centrally nucleated fibers and the CSA of single 
muscle  fibers  were  determinate  by  using  ImageJ  software  (NIH, 
Bethesda, MD) on calibrated images of cryosections stained with Gömöri 
Trichrome.
Characterization of fibrotic and fat tissue in the muscle was performed 
after Sirius Red and Oil Red O staining, respectively. The tissues were 
quantified measuring the percentage of red area in the sections (ImageJ, 
NIH).
For CD45 immunohistochemistry, cryostat sections were air-dried 
and fixed in prechilled acetone for 10 minutes. Endogenous peroxidase 
was inhibited by incubation for 10 minutes at room temperature with 
methanol plus 0.03% hydrogen peroxide. Tissue sections were incubated 
overnight  at  4 °C  with  rat,  anti-mouse  CD45  antibody  (BD,  Franklin 
Lakes, NJ) diluted 1:500. Then samples were incubated with 1:300 dilution 
of an anti-rat antibody conjugated with biotin (#13-4813-85; eBioscience, 
San Diego, CA). Avidin-biotin-peroxidase complex was added (Vector 
lab, Burlingame, CA) and sections were incubated for 5–10 minutes with 
a DAB substrate (Dako, Glostrup, Denmark) and counterstained with 
hematoxylin and mounted.
For  dystrophin  immunofluorescence,  cryostat  sections  were 
permeabilized with 0.2% TritonX100 and 1% bovine serum albumin for 
15 minutes. After a blocking of 30 minutes in 0.2% TritonX100, 1% bovine 
serum albumin and 10% goat serum, the sections were incubated O/N 
with a mix of two anti-mouse Dystrophin antibodies (NCL-Dys1 and 
NCL-Dys2; Novacastra, Leica Microsystem, Wetzlar, Germany) diluted 
1:50. Then samples were incubated for 1 hour with 1:500 dilution of a 
goat anti-mouse Alexa Fluor 555 (Invitrogen, Cergy-Pontoise, France). 
Finally, nuclei were stained by Hoechst3342 and section were mounted in 
phosphate-buffered saline 90% glycerol.Molecular Therapy  vol. 19 no. 11 nov. 2011  2063
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For the analysis of human alkaline phosphatase (hPLAP) activity, 
muscles cryosections were fixed in 4% paraformaldehyde for 10 minutes, 
incubated  at  65 °C  for  90  minutes  to  inactivate  endogenous  APs  and 
stained at room temperature protected from the light with BCIP/NBT 
substrate (Roche, Basel, Switzerland) in a buffer containing 100 mmol/l 
Tris-HCl  pH  9,  150 mmol/l  NaCl,  1 mmol/l  MgCl2,  0.001%  Tween20. 
Next, sections were dehydrated in an alcohol scale and mounted.
Following  euthanization,  mouse  livers  and  heart  specimens  were 
collected and paraffin embedded. Sections of 8 µm were cut and stained 
with hematoxylin and eosin.
RNA  isolation  and  real-time  RT-PCR.  Total  RNA  was  extracted  from 
cells  with  PureLink  RNA  MiniKit  (Invitrogen,  Carlsbad,  CA)  follow-
ing  the  manufacturer’s  instructions.  Dissected  muscles  were  disrupted 
by TissueLyser (Qiagen, Hilden, Germany) and RNA was isolated using 
RNeasy fibrous tissue kit (Qiagen).
Equal  amounts  of  RNA  for  each  sample  were  retrotranscribed 
with  SuperScript  III  First-Strand  Synthesis  SuperMix  (Invitrogen, 
Carlsbad, CA) following the manufacturer’s conditions. In brief, RNA 
was retrotranscribed with a 1:1 mix of oligo(dT) and random hexamer 
primers  and  with  SuperScript  III  Reverse  Transcriptase  (Invitrogen, 
Carlsbad, CA). After treatment, the complementary DNAs were digested 
with RNaseH for 20 minutes at 37 °C.
For gene expression analysis, real-time PCR with Sybr GreenER qPCR 
kit (Invitrogen, Carlsbad, CA) was used. Each sample was run in triplicate 
with specific primers for FRG1 (forward 5′-AGTCCTCCAGAGCAGTT 
TAC-3′,  reverse  5′-AATAAAGCAGCTATTTGAGGC-3′)  and 
hPLAP  (forward  5′-GGTGAACCGCAACTGGTACT-3′,  reverse   
5′-CCCACCTTGGCTGTAGTCAT-3′). IL-10 (forward 5′-ATTTG-AAT 
TCCCTGGGTGAGAAG-3′,  reverse  5′-CACAGGGGAGAAATCGATG 
ACA-3′) and TNF-α (forward 5′-TCCCAGGTTCTCTTCAAGGGA-3′, 
reverse 5′-GGTGAGGAGCACGTAGTCGG-3′).
For sample normalization, GAPDH (forward 5′-TCAAGAAGGTG 
GTGAAGCAGG-3′, reverse 5′-ACCAGGAAATGAGCTTGACAAA-3′) 
or  ACTN3  (forward  5′-GGGGCGGCGAGTACATGGAAC-3′,  reverse 
5′-CAGTGAAGGTTTTCCGCTGCTGT-3′) were used in cell or muscle 
samples,  respectively.  The  PCR  conditions  were  the  following:  initial 
denaturation at 95 °C for 10 minutes, 40 cycles with denaturation at 95 °C 
for 30 seconds, annealing at 58 °C for 30 seconds and amplification at 
72 °C for 30 seconds.
Gene expression of IL-10 (forward 5′-ATTTG-AATTCCCTGGGT 
GAGAAG-3′,  reverse  5′-CACAGGGGAGAAATCGATGACA-3′)  and 
TNF-α (forward 5′-TCCCAGGTTCTCTTCAAGGGA-3′, reverse 5′-GG 
TGAGGAGCACGTAGTCGG-3′)  was  normalized  versus  GAPDH  and 
the conditions of the PCR were the following: 50 °C for 2 minutes, 95 °C 
for 10 minutes, 40 cycles with 95 °C for 15 seconds and 60 °C for 1 minute. 
Melting curves were performed at the end of each amplification reaction 
to monitor product specificity.
Viral genome quantification. Vector genomes per nuclei from injected 
mice  were  determined  by  real-time  qPCR  on  an  ABI  Prism  7500 
(Perkin Elmer, Waltham, MA) with primers to the SV40 polyadenyla-
tion  signal  [forward-  5′  TTTTCACTGCATTCTAGTTGTGGTT  3′ 
and  reverse-  5′  CATGCTCTAGTCGAGGTCGAGAT  3′  with  probe 
5′  6FAM-ACTCATCAATGTATCTTATCATG-MGBNFQ  3′  (Applied 
Biosystems, Austin, TX)]. Nuclear mouse Ldlr was quantified [forward 
primer-  5′  CGTGCTCCCAGGATGACTTC  3′  and  reverse  primer  5′ 
CTCCATCACACACAAACTGCG 3′ and detected with probe- 5′ 6FAM-
ATGCCAGGATGGCAAGTGCATCTCC-TAMRA  (Operon,  Huntsville, 
AL)] and used to determine the vector genomes per nuclei (vg/n) based on 
the number of genomes/(number of copies of Ldlr/2).
Western  blotting.  Cells  or  dissected  muscles  were  homogenized  in 
RIPA  buffer  (50 mmol/l  Tris  pH  =  7.4,  150 mmol/l  NaCl,  1%  Triton 
X100, 1% deoxycholic acid, 0.1% sodium dodecyl sulfate) supplemented 
with a cocktail of protease inhibitors (Complete Tablets; Roche, Basel, 
Switzerland) using a TissueLyser (Qiagen). Samples were incubated for 
30 minutes on ice and centrifuged at 16,500g for 10 minutes at 4 °C. The 
supernatant was removed and centrifuged again. Protein concentration 
of the final supernatant was measured using the Bradford assay (Pierce, 
Rockford, IL). Ten micrograms of protein extracts were separated using 
a  10%  sodium  dodecyl  sulfate-polyacrylamide  gel    electrophoresis 
gel  and  transferred  onto  a  nitrocellulose  membrane  (GE  Healthcare, 
Buckinghamshire,  UK).  Immunoblots  were  incubated  with  primary 
antibodies  against  either  human  FRG1  (mouse  monoclonal,  1:500, 
sc-101050;  Santa  Cruz,  San  Diego,  CA)  or  HA  (mouse  monoclonal, 
1:500 #MMS-101; Covance, Princeton, NJ). Subsequently, 1:10,000 dilu-
tion  peroxidase-conjugated  donkey  anti-mouse  IgG  (#715-035-015; 
Jackson ImmunoResearch, West Grove, PA) was added. Detection was 
performed  by  super  signal  west  pico  chemioluminescence  substrate 
(Thermo Scientific, Waltham, MA). Homogeneous sample loading was 
verified with an anti-α tubulin antibody (T9026; Sigma, St Louis, MO) 
at 1:10,000 dilution.
Blood  analysis. The extent of hepatocellular injury was monitored by 
measuring  serum  alanine  aminotransferase  activity  at  multiple  time 
points after AAV injection. Serum alanine aminotransferase activity was 
measured with a IFCC (International Federation of Clinical Chemistry 
and  Laboratory  Medicine)  optimized  kinetic  UV  method  in  a  SABA 
chemical analyzer (SEAC-RADIM, Firenze, Italy) and expressed as U/L 
(Units/Liter).
Functional analysis. Three groups of mice (wild type n = 4 age- and sex-
matched, transgenic FRG1 vector-injected n = 5, transgenic FRG1 vehi-
cle-injected n = 5) were subjected to an exhaustion treadmill test from 1 
to 12 weeks after treatment. Each mouse was placed on the belt of a six-
lane  motorized  treadmill  (Exer  3/6  Treadmill;  Columbus  Instruments, 
Columbus, OH) supplied with shocker plates. The treadmill was run at an 
inclination of 0° initially at 4 m/minute for 2 minutes and the speed was 
then increased 2 m/minute every 2 minutes at an inclination of 0°. The test 
was stopped when the mouse remained on the shocker plate for more than 
20 seconds without attempting to re-engage the treadmill, and the time to 
exhaustion was determined.
miRNA extraction and quantitative RT-PCR analyses. Small RNAs were 
isolated from the heart, liver and skeletal muscles of FRG1 overexpressing 
mice infected with AVV6-sh1FRG1 (n = 3) or vehicle alone (n = 3) using 
miRNeasy FFPE kit (liver and heart) (Qiagen) or miRNeasy mini kit (skel-
etal muscles) (Qiagen). For miRNA detection, RNA was retrotranscribed 
and quantified by qPCR using the TaqMan MicroRNAs assay (Applied 
Biosystems). SnoRNA55 was used to normalize the expression and quanti-
tative PCR was performed on a ViiA7 (Applied Biosystems).
Statistical  analysis.  All data are expressed as means ± SD. Difference 
between two groups was tested by means of two-tail t-test for indepen-
dent samples. A Kolmogorov–Smirnov test was performed to determine 
whether the fiber distribution was similar in different samples.
suPPleMentArY MAterIAl
Figure S1.  Absence of toxicity in liver and heart of rAAV6-sh1FRG1 
treated mice.
Figure S2. Absence of toxicity in muscle and normal miRNA expres-
sion following rAAV6-sh1FRG1 treatment.
Figure S3. rAAV6-sh1FRG1 reduces fibrosis in FRG1 overexpressing 
mice muscles.
Figure S4. rAAV6-sh1FRG1 reduces fat deposition in FRG1 overex-
pressing mice muscles.
Figure S5. rAAV6-sh1FRG1  reduces  inflammation  in  FRG1  overex-
pressing mice muscles.
Video S1. Treated FRG1 mice show improved running endurance.2064  www.moleculartherapy.org  vol. 19 no. 11 nov. 2011     
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